Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprepitant prophylaxis for chemotherapy-induced nausea and vomiting with docetaxel-cyclophosphamide in early breast cancer
2010-022689-29Phase 4Active
- Sponsor
- GEICAM
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aprepitant in chemotherapy-induced nausea and vomiting (CINV), sponsored by GEICAM. Primary endpoints: Incidence of chemotherapy-induced nausea and vomiting associated with docetaxel-cyclophosphamide and Complete response in cycle 1. Started Nov 2010; status: active.
02
Drugs
aprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on 2010-022689-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022689-29.